Evaluation of β-Arrestin1 and Total Protein in Patients with Metabolic Disorders

Abstract

Metabolic disorders are serious and complex syndromes characterized by a group of diseases, such as abdominal obesity, dyslipidemia, blood pressure, hyperglycemia, vascular disease, type 2 diabetes, chronic kidney disease, stroke, and cancer. The aim of the study is to evaluate both the biomarker β-arrestin 1and total protein in patients with metabolic disorders and to find the relationship between them. Samples were collected from Al-Yarmouk Teaching Hospital; with a total of 135 samples selected for the study. The groups were divided according to body mass index (BMI) and metabolic diseases into three groups: G1 includes 46 healthy subjects that represent the control group, patients group with metabolic disorders (G2, n=45), and patients with T2DM who have obesity (G3, n= 44). The age range of the participants was (30 -55) years. The β-arrestin 1, and insulin were evaluated using ELISA, Al-Kit and technology from Huma Reader HS made in (USA). The results indicate that there was a significant difference between the three groups Total Protein(g\dL) [G1(5.48±0.12), G2 (6.02±0.07), G3 (6.93±0.14)], and β-arrestin 1 (pg\mL) [ G1(273.98±21.30) G2 (311.16± 20.23) G3(520.75±27.25 )]. The results showed a negative correlation between total Protein and β-arrestin 1in G3 (r=-0.385) but no correlation G1and G2. β-arrestin 1gave a very good result area under the curve (AUC)   is a biomarker for predicting metabolic disorders, and total protein is also a biomarker for predicting metabolic disorders.